FINWIRES · TerminalFinancial News · Live TerminalLIVE

HKG:2005

21 stories mentioning HKG:2005Updated 9d ago

Every FINWIRES story that references HKG:2005, newest first.

SSY Group Gets China Nod to Produce, Register Four Drugs

SSY Group (HKG:2005) obtained drug production and registration approvals for four products from China's National Medical Products Administration as they pass the regulator's consistency evaluation.The approvals are for Hemofiltration Replacement Fluid of Sodium Citrate used as replacement fluid in continuous renal replacement therapy and Benidipine Hydrochloride Tablets for the treatment of primary hypertension and angina pectoris.The other two products comprise Polyvinyl Alcohol Eye Drops as a lubricant for dry eyes and a Fat Emulsion, Amino Acids and Glucose Injection for adult patients.

SSY Group's Gadobutrol Bulk Drug Wins China Registration Approval

SSY Group (HKG:2005) said its Gadobutrol bulk drug has received marketing registration approval from China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The approval allows the active pharmaceutical ingredient to be used in marketed Gadobutrol preparations.Gadobutrol is a magnetic resonance imaging contrast agent used in adults and children for contrast-enhanced MRI and magnetic resonance angiography examinations, the filing said.

SSY Group Secures China Approval for Choline Fenofibrate Capsules

SSY Group (HKG:2005) said its Choline Fenofibrate Sustained-release Capsules have received drug registration approval from China's National Medical Products Administration, according to a Thursday filing with the Hong Kong bourse.The product is approved as a Class 4 chemical drug and has passed the consistency evaluation.Choline Fenofibrate Sustained-release Capsules are used to lower triglyceride levels in adults with severe hypertriglyceridemia and to treat patients with primary hypercholesterolemia or mixed dyslipidemia, the filing said.

SSY Group Secures China Approval for Baloxavir Marboxil Bulk Drug

SSY Group (HKG:2005) said its Baloxavir Marboxil has received registration approval from China's National Medical Products Administration as a bulk drug for marketed preparations, according to a Hong Kong bourse filing Monday.Baloxavir Marboxil is used to treat influenza A and influenza B, the filing said.

SSY Group Gets Production, Registration Nod for Two Drugs in China

SSY Group (HKG:2005) obtained production and registration approval for the Propylthiouracil Tablets and Calcium Gluconate and Sodium Chloride Injection from China's National Medical Products Administration.The move came as the drugs were regarded as passing the regulator's consistency evaluation, according to a Friday Hong Kong bourse filing.The Propylthiouracil Tablets are mainly used for various types of hyperthyroidism intolerant to methimazole.The Calcium Gluconate and Sodium Chloride Injection is used to treat acute hypocalcemia, magnesium poisoning, and fluoride poisoning, and has formed a calcium preparation product series along with the company's other products.

SSY Group Adds 32 Products to China's Essential Medicines List

SSY Group (HKG:2005) said 32 of its products, comprising 37 specifications, were newly included in the 2026 edition of China's National Essential Medicines List.This brings the total number of the group's products on the list to 95, covering 141 specifications, according to a Friday Hong Kong bourse filing. The updated list will take effect on Sept. 1.The pharmaceutical company said the inclusion is expected to support its business growth and development.Shares of the pharmaceutical company rose 2% in recent trade.

SSY Gets China Production Nod for Methocarbamol Tablets, Registers Phloroglucinol Dihydrate

SSY Group (HKG:2005) obtained production and registration approval for Methocarbamol Tablets and registration approval for Phloroglucinol Dihydrate from China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.The approval for Methocarbamol Tablets came as the drug passed the regulator's consistency evaluation.Methocarbamol Tablets are muscle relaxants mainly used to treat joint and muscle sprains, lumbar muscle strain, and sciatica.Phloroglucinol Dihydrate is used to treat acute spasmodic pain associated with digestive, biliary, urinary, and gynecological conditions.Shares of the firm were up nearly 5% in late morning trade on Thursday.

SSY Gets Production, Registration Nod for Two Drugs in China

SSY Group (HKG:2005) obtained production and registration approvals for Safinamide Mesylate Tablets and Procaterol Hydrochloride Inhalation Solution from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.The approval came as the drugs passed the regulator's consistency evaluation.Safinamide Mesylate Tablets are mainly used in adult patients with primary Parkinson's disease and symptom fluctuation, in combination with other drugs for Parkinson's.The Procaterol Hydrochloride Inhalation Solution is used to provide relief for airflow limitation symptoms in bronchial asthma, chronic bronchitis, and emphysema.

SSY Group Gets Production, Registration Nod for Infection Drug in China

SSY Group (HKG:2005) obtained production and registration approval for Cefpodoxime Proxetil for Suspension from China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The move came after the drug was regarded as passing the regulator's consistency evaluation, the pharmaceutical company said.The drug is used to treat infections caused by susceptible bacteria, including upper and lower respiratory tract, uncomplicated urinary tract, and uncomplicated skin and soft tissue infections.The drug also treats acute uncomplicated gonococcal urethritis and cervicitis, as well as perianal inflammation caused by Neisseria gonorrhoea.

SSY Group Unit Enters Talks Over Dialysis Drug

SSY Group (HKG:2005) said its Shijiazhuang No. 4 Pharmaceutical unit is negotiating an exclusive license for peritoneal dialysis treatment OPT101, according to a Monday filing with the Hong Kong bourse.The firm signed a letter of intent with the drug's developer, Opterion Health, for a possible license covering China that would expire in 2038. The SSY Group unit will also receive priority over licenses covering Hong Kong, Taiwan, and Russia.A formal agreement is expected in the third quarter of 2026, SSY Group said.Shares of SSY gained over 1% in recent trade.

SSY Group Enters Negotiations Over 4 Biosimilars With Longhai Pharmaceutical

SSY Group (HKG:2005) said it entered exclusive negotiations with Hebei Longhai Pharmaceutical over four biosimilar drugs, according to a Friday filing with the Hong Kong bourse.Under the letter of intent, the firm may license biosimilar versions of ustekinumab, dupilumab, aflibercept, and evolocumab from Longhai Pharmaceutical, which will be responsible for completing research and technical know-how on the medicines.The company will be required to make a down payment and milestone payments to Longhai Pharmaceutical if the deal materializes.The exclusivity period for negotiations will last 90 days, the firm said.

SSY Group Gets Bulk Drug Approval for Parkinson's Disease Treatment in China

SSY Group (HKG:2005) obtained registration approval for Safinamide Mesylate to become a bulk drug for the preparations on the market from China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The drug is mainly used for the treatment of Parkinson's disease in combination with other Parkinson's drugs such as levodopa, the filing said.

SSY Group Gets Various Drug Registration, Production Approvals in China

SSY Group (HKG:2005) has obtained approval from China's National Medical Products Administration for the production and registration of three drugs, according to a Thursday filing with the Hong Kong bourse.The drugs comprise Emedastine Difumarate Eye Drops for temporary relief from allergic conjunctivitis, Perindopril Arginine Tablets to treat hypertension and congestive heart failure, and Peramivir and Sodium Chloride Injection 100ml to treat influenza A and B.The approval came as the drugs are regarded as passing the regulator's consistency evaluation.The pharma firm also obtained approval for the Bumetanide Injection after it was regarded as passing the consistency evaluation. The product is mainly used for the treatment of hypertension and edematous diseases.

SSY Group Gets Bulk Drug Approval for Hypertension Drug in China

SSY Group (HKG:2005) obtained registration approval for Azilsartan Medoxomil Potassium to become a bulk drug for the preparations on the market from China's National Medical Products Administration.The drug is used to treat primary hypertension in adults, according to a Thursday filing by the pharmaceutical firm with the Hong Kong bourse.

SSY Group Receives China Approval for Three Drugs

Pharmaceutical firm SSY Group (HKG:2005) received drug production and registration approvals for three products in China, according to a Hong Kong bourse filing Monday.The approval from China's National Medical Products Administration covers oseltamivir phosphate capsules to treat influenza A and B; drotaverine hydrochloride tablets to treat smooth muscle spasms; and metoclopramide tablets for nausea.

SSY Group Gets China Nod for Vitamin B12 Injection

SSY Group (HKG:2005) obtained approval for its Cyanocobalamin (Vitamin B12) Injection from China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.The approval came as the drug passed the regulator's consistency evaluation of the quality and efficacy of generic drugs.The injection is primarily used for megaloblastic anemia caused by intrinsic factor deficiency such as neuritis, the pharma firm said.

SSY Group's Protein Test Kits Get Device Registration Certificates from Hebei Regulator

SSY Group's (HKG:2005) full-range C-reactive and Serum Amyloid A/C-reactive protein test kits obtained medical device registration certificates from the Hebei Provincial Drug Administration of China, according to a Wednesday Hong Kong bourse filing.The kits are used for in vitro quantitative detection of C-reactive protein and serum amyloid A levels in human serum, plasma, or whole blood samples.

SSY Group Receives China Approval for Three Drugs

Pharmaceutical firm SSY Group (HKG:2005) said it received drug production and registration approvals for three of its products in China, according to a Hong Kong bourse filing Wednesday.The approval from China's National Medical Products Administration covers a fat-soluble vitamin injection, metformin hydrochloride tablets for type 2 diabetes, and doxazosin mesylate extended release tablets for benign prostatic hyperplasia and hypertension.

SSY Group's Attributable Profit, Turnover Rise in Q1

SSY Group (HKG:2005) reported unaudited profit attributable to shareholders of the company of HK$171.2 million for the quarter ended March 31, up from HK$168.5 million in the year-ago period, according to a Hong Kong bourse filing on Monday.The Hong Kong-listed pharmaceutical product maker's turnover in the first quarter reached HK$1.23 billion, compared with HK$1.14 billion a year ago.

SSY Group Gets Chinese Regulatory Nod for Production, Registration of Two Products

SSY Group (HKG:2005) said it received Chinese regulatory approval to begin drug production and registration of its diltiazem hydrochloride in injection form, according to a Hong Kong bourse filing Monday.The drug is mainly used to treat a heart condition known as supraventricular tachycardia and the emergency treatment of abnormally high blood pressure during surgery.The firm's propranolol hydrochloride injection was also approved for production and registration by China's National Medical Products Administration.The product is mainly used to treat supraventricular tachyarrhythmias and ventricular arrhythmias.

Showing 1-20 of 21

Track with the FINWIRES app suite

Track HKG:2005 in your portfolio

Analyze HKG:2005 options with the wheel strategy

See market sentiment on HKG:2005